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Summary
Both the protein used and the conjugation method are factors which may be relevant for targeting 
infection with n lIn-labelled proteins. In this study, human immunoglobulin G (IgG), conjugated to either 
DTPA or LiLo, and LiLo conjugated human immunoglobulin M (IgM) were evaluated. In rats with 
Staphylococcus aureus calf muscle infection, biodistribution was determined 6, 24 and 48 h after the 
injection of l1lIn-DTPA-IgG, lnIn-LiLo-IgG or ln In-LiLo-IgM, Absolute abscess uptake of n lIn-LiLo-IgG 
was significantly higher than that of u1In-DTPA-IgG (P <  0.05). Since blood clearance of n lIn-LiLo-IgG 
was initially significantly slower (P <  0.01), the higher abscess uptake did not result in higher abscess-to- 
background ratios. m In-LiLo-IgG accumulated to a greater extent in the liver (P <  0.001). m In-DTPA- 
IgG showed higher uptake in the kidneys and bone marrow (P <  0.001 and P <  0.01, respectively). 
Although decreasing over time, m In-LiLo-IgM showed reasonable abscess uptake and rapid blood clear­
ance, resulting in higher abscess-to-background ratios compared with m In-LiLo-IgG (P <  0.01). How­
ever, liver and spleen uptake were three- to four-fold higher than that of rnIn-LiLo-lgG (P <  0.001). 
Compared with DTPA-conjugation, chelation with LiLo has a minor influence on abscess targeting of 
m In-labelled IgG. However, differences in blood clearance and organ uptake do occur. n lIn-LiLo-IgM 
shows high relative accumulation in abscesses as well as high liver and spleen uptake. ntIn-LiLo- 
IgM appears promising for imaging infection outside the trunk region.
Introduction
A number of studies have demonstrated the utility Of 
m In-labelled non-specific polyclonal human immuno­
globulin G (niIn-IgG) scintigraphy for the detection of 
various types of focal infection in humans [1, 2]. In a 
clinically used formulation, the protein is conjugated 
with the bifunctional chelating agent diethylenetria- 
mine-pentaacetic (DTPA) cyclic anhydride for labelling 
with m In. However, the chelator may play an important 
role in the distribution of the radiolabel in various tis­
sues [3]. Release of m In from the conjugates produces a 
continuous leakage of radionuclide into the blood, 
resulting in transport through transferrin to the liver and 
other organs of the mononuclear phagocytic system [4], 
It has been suggested that l,3-bis[N-[N-(2-aminoethyl)-
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2-aminoethyl]- 2 - aminoacetamido] - 2 -4 - (isothiocynnnlo-
benzyl) propane-N, N , N', N " , N 'u, N "" , N ..., N....-octaac-
etic add (LiLo) forms a kinetically more stable complex 
for binding 111 In to proteins [3], In the first part of Hie 
study, IgG conjugated to either DTPA or LiLo and subse­
quently labelled with 111 In was studied in a rat model of 
infection.
Not only may the ligand be relevant for biodislrilni- 
tion, but the protein may also play an important role [5]. 
As reported previously, proteins smaller than IgG (such 
as human serum albumin) accumulate in a similar fash­
ion to IgG in experimental infection. However, the back­
ground activity is higher, due to the higher influx into 
the non-target tissues [5, 6], resulting in lower abscess- 
to-background ratios of albumin compared with IgG 
[5], In the second part of the study, IgM (molecular 
weight 900 kDa, which is five times larger than IgG) 
was radiolabelled with rnIn after LiLo conjugation and 
compared with m In-LiLo-IgG.
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Materials and methods
Radiopharmaceuticals
IUIn-D T P A -lgG . The bifunctional chelating agent DTPA 
bicyclic anhydride was conjugated to IgG (Sandoglobu- 
lin, Sandoz AG, Nürnberg, Germany) as described pre­
viously [7]. Conjugation of DTPA to IgG resulted in two 
to three DTPA ligands per protein molecule.
m In-L iLo-IgG  and m In-LiLo-IgM . As described earlier, 
the bifunctional chelating agent LiLo was conjugated to 
IgG (Sandoglobulin, Sandoz AG, Nürnberg, Germany) 
and to the human monoclonal IgM antibody 16.88, direc­
ted against an intracellular epitope in adenocarcinoma 
cells (Perimmune Inc./Akzo Nobel, Rockville, MD, 
USA) [3]. Conjugation of LiLo to the proteins resulted in 
three to four LiLo ligands per protein molecule.
R adiolabelling and dosing
Aliquots of 0.5 mg of the conjugate were radiolabelled 
with in In (Indium chloride, Mallinckrodt Medical, Pette, 
The Netherlands) via citrate transchelation [5], The 
radiochemical purity of the radiolabelled proteins was 
determined by instant thin-layer chromatography (ITLC) 
on Gelman ITLC-SG strips (Gelman Laboratories, Ann 
Arbor, MI) with 0.1 m citrate (pH = 5) as solvent. The 
labelling efficiency was always higher than 95%. A dose 
of 10 pg, labelled with 2 MBq m In, was injected intra­
venously.
A n im a ls  and  stu d y  design
In young, male, randomly bred Wistar rats (weight 
200-220 g), a calf muscle abscess was induced after ether 
anaesthesia with approximately 2x l08 colony-forming 
units of Staphylococcus aureus in 0.1 ml of a 50:50 (v/v) 
suspension of autologous blood and normal saline. The 
animals were randomly divided into groups. Twenty- 
four hours after the inoculation of S. aureus in the mus­
cle, when swelling of the muscle was apparent, the 
respective radiopharmaceuticals were injected via the 
tail vein.
For tissue collection, the rats were killed with 30 mg 
phenobarbital injected intraperitoneally, followed by cer­
vical dislocation at 6, 24 and 48 h post-injection. Each 
protein was evaluated in five animals at each time point. 
Samples of bone marrow (taken from the right femur) 
and blood were collected. The infected left calf muscle, 
the right calf muscle, liver, spleen, kidneys, lung, duode­
num and the right femur were dissected and blotted dry. 
The activity in the tissues and samples was measured in 
a shielded well-type gammacounter. To correct for radio­
active decay and permit calculation of the uptake of the 
radiopharmaceuticals in each organ as a fraction of the 
injected dose, aliquots of the respective doses were coun­
ted simultaneously. The activity measured in the tissues
and samples was expressed as a percentage of the injec­
ted dose per gram (% i.d. g ~ ') and the excreted activity 
per animal as a percentage of the total dose adminis­
tered.
For calculation of background activity, we used a com­
bination of normal muscle activity and blood activity as 
described previously [5], Since the blood volume of rats 
approximates to 60 ml per kg body weight (6%), 
94% x the activity per gram in muscle plus 6%xthe 
activity per gram in blood was adopted as the value for 
background activity [8]. Abscess-to-background ratios 
were also calculated.
Statistical analysis
All mean values are given as % i.d. g _1 or ratios ± one 
standard error of the mean (s.e.m.). Statistical analysis 
was performed using one-way analysis of variance 
(ANOVA). The level of significance was set at 
P  <  0.05.
Results
Comparison of m In-D TPA-lgG  and m In-LiLo-IgG  
As shown in Table 1, conjugation of IgG with LiLo resul­
ted in a marginally higher amount of abscess uptake of 
rnIn-LiLo-IgG compared with inIn-DTPA-IgG. Only at 
48 h post-injection was a significant difference observed 
(P < 0.05). As shown in Fig. 1, abscess-to-background 
ratios were similar at all time points. At 6 and 24 h post­
injection, blood levels of n iIn-LiLo-IgG were signifi­
cantly higher (P < 0.001-P < 0.01). As indicated in 
Table 2, m In-LiLo-IgG showed relatively high liver 
uptake (P < 0.001), while the renal uptake of rnIn- 
DTPA-IgG was significantly higher (P < 0.001- 
P  <  0.01). In spleen, lungs, bowel and initial bone 
marrow, the uptake of both agents was similar. At 48 h 
post-injection, bone marrow uptake of m In-DTPA-IgG 
was slightly, but significantly, higher (P <  0.05).
Comparison o f m In-LiLo-lgG and m ln-L iLo-IgM  
As shown in Table 1, the uptake of m In-LiLo-IgM in the 
abscess was significantly lower compared with that of 
m In-LiLo-IgG (P < 0.001-P < 0.01). While the m In- 
LiLo-IgG concentration in the abscess remained constant, 
significant washout of ulIn-LiLo-IgM was observed over 
time (P < 0.05). rnIn-LiLo-IgM cleared significantly 
faster from the blood than luIn-DTPA-IgG (P <  0.001). 
Due to this faster background clearance, the abscess-to- 
background ratios of 111In-LiLo-IgM increased with time 
and were significantly higher than the ratios obtained 
with lu In-LiLo-IgG (P < 0.001). As indicated in Table 2, 
n iIn-LiLo-IgM was in the main taken up in liver and 
spleen (P < 0.001), while renal, pulmonary and initial 
bowel uptake were significantly lower than those of
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Table 1. Mean (± s.e.m.) abscess, muscle and blood activity (% i.d. g J) and abscess-to-background ratio 6, 
24 and 48 h post-injection (p.i.).
Time p.i. (h) m ln-DTPA-IgG m In-LiLo-IgG m In-LiLo-IgM
Abscess 6 1.08 ±0.05 1.21+0.08 b 0.78 ±0.06
24 1.09 ±0.07 1.22 ±0.11 b 0.64 ±0.07
48 1.09'+0.03 1.34 ±0.10 c 0.57 ±0.05
Muscle 6 0.13 ±0.01 0.11 ±0.01 0.06 ±0.01
24 0.16 ±0.02 0.14 ±0.02 0.03 ±0.01
48 0.16 ±0.01 0.17 ±0.02 0.03 ±0.01
Blood 6 2.58 ± 0.09 c 3.20 ±0.09 c 1.37 ±0.23
24 1.11 ±0.04 b 1.53 ±0.10 c 0.13 + 0.03
48 0.69 ± 0.04 0.99 ±0.14 c 0.02 ±0.01
Abscess-to-background ratio 6 3.94 ±0.24 4.16 ±0.29 6.63 ±1.62
24 4.42 ± 0.46 5.14 ±0.52 b 14.46 ±2.48
48 5.99 ± 0.29 6.20 ±0.29 b 19.69 ±3.69
"P <  0.05; bP <  0.01; CP <  0.001.
Fig. 1. Abscess-to-background 
ratios (the error bars indicate the
S.E.M.
in In-LiLo-IgG (P <  0.001-P <  0.05). The bone marrow 
uptake of both radiopharmaceuticals was similar.
Discussion
The first aim of this study was to evaluate the possible 
advantage of using a more stable chelating agent than 
DTPA, such as LiLo [3], for in In labelling of IgG. DTPA- 
and LiLo-conjugated IgG showed similar abscess uptake 
and abscess-to-background ratios, indicating a more sta­
ble n iIn-labelled complex is not necessarily better suited 
for the detection of abscesses. It would appear that the
Nuclear Medicine Communications (1996) 17
stability of m In-DTPA-IgG is sufficiently high to enable 
adequate abscess accumulation. It has been show n that 
the dissociation and subsequent entrapment of rad ionu­
clide in the extracellular matrix is an important factor in 
m In uptake in experimental abscesses after the injection 
of m In-DTPA-IgG, while the protein or pro tein  frag­
ments are split off and washed out [9, 10]. Therefore, 
more stable in In chelation will not automatically result 
in higher abscess uptake. The increased stability of the 
LiLo complex may be reflected in the slower b lood  clear­
ance and lower bone marrow uptake. Uptake in  organs 
was also affected: in In-LiLo-IgM accum ulated to a 
greater extent in liver, whereas u lIn-DTPA-IgG show ed
Table 2. Mean (± s.e.m.) tissue uptake (% i.d. g-1) 6, 24 and 48 h post-injection (p.i.).
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Time p.i. (h) nlIn-DTPA-IgG m In-LiLo-IgG m ln-LiLo-IgM
Liver 6 0.90 ± 0.02 C 1.90 ±0.07 c 4.33 ± 0.23
24 0.91 ±0.05 c 2.11 ±0.02 c 5.43 ±0.24
48 1.02 ±0.02 c 2.77 ±0.40 c 4.97 ±0.17
Spleen 6 1.16 ±0.06 1.26 + 0.03 c 4.40 ± 0.59
24 1.40 ±0.06 1.41 ±0.08 c 3.66 ±0.24
48 1.56 ±0.06 1.80 + 0.14 c 3.33 ±0.10
Kidney 6 3.67 + 0.13 c 2.29 ±0.21 c 1.16 ±0.08
24 3.80 ±0.14 h 2.99 ± 0.23 c 1.12 ±0.05
48 3.75 ±0.07 c 2.66 + 0.16 c 1.07 + 0.05
Lung 6 0.98 ± 0.03 1.09 + 0.06 c 0.49 ± 0.04
24 0.54 ±0.01 0.64 ± 0.04 c 0.11 ±0.02
48 0.43 ± 0.01 0.51 ± 0.05 c 0.08 ±0.01
Bone marrow 6 1.23 ±0.09 1.10 + 0.08 1.16 ±0.09
24 0.99 ± 0.11 0.74 ± 0.14 0.78 ±0.06
48 1.17 ±0.03 11 0.83 ±0.06 0.78 ±0.10
Bowel 6 0.36 ± 0.02 0.36 ±0.02 n 0.28 ±0.02
24 0.27 ±0.01 0.26 ±0.01 a 0.22 ±0.01
48 0.23 ±0.01 0.23 ± 0.01 0.20 ±0.02
"P < 0.05; "P < 0.01; 'P < 0.001.
higher renal uptake. Our data in rats with infection con­
cur with previous studies in tumour-bearing athymic 
mice in which four different inIn-chelate-antibody com­
plexes showed similar tumour uptake but a very differ­
ent distribution in organs [4], Other studies have 
indicated that the most striking differences between 
radiometal-DTPA-antibody complexes and more stable 
chelates occur after the first 48 h post-injection [11, 12].
The second aim of the study was to evaluate the pos­
sible advantage of using a protein larger than IgG for the 
detection of infection. Striking differences were observed 
when we compared m In~LiLo-IgG with m In-LiLo-IgM. 
Although absolute abscess uptake of IgM was lower, 
abscess-to-background ratios were up to three times 
higher due to the very fast clearance from the back­
ground. As IgM is relatively large compared with IgG 
(900 vs 150 kDa), one might assume that penetration into 
an abscess would be more difficult. Although the ab­
solute uptake of IgM was as much as half that of IgG, it 
should be sufficiently high to make adequate imaging of 
foci possible. In contrast to the uptake of lu In in an 
abscess after in In-LiLo-IgG injection, which remains rel­
atively stable over time, ln In-LiLo-IgM uptake 
decreased in the abscess. This can be explained by the 
relatively fast clearance from blood and background 
compared with IgG, allowing niIn-LiLo-IgM washout 
from the abscess. These findings are similar to those in
previous studies with m In-DTPA-IgA [5]. u lIn-DTPA- 
IgA cleared even faster from the blood pool to liver, 
spleen and also kidneys than in In-LiLo-IgM. m In- 
DTPA-IgA was washed out of the abscess, while abscess- 
to-background ratios increased with time [5].
The rapid blood and background clearance of ln In- 
LiLo-IgM was most probably due to fast, high uptake in 
liver and spleen. A liver uptake of 5% i.d. g _1 in a rat 
indicates total liver uptake of as much as 60%,i.d. Such 
high physiological liver uptake makes the agent unsuit­
able for imaging in the upper abdominal area. The much 
lower liver uptake of m In-DTPA-IgG is already known 
to obscure infectious lesions in the liver [13]. In areas 
outside the vicinity of the liver, liver uptake is irrelevant. 
Here, the high target-to-background ratios may prove 
advantageous, for example in the evaluation of infection 
of the peripheral locomotor system [1,14], Similar to the 
low background activity, the uptake of m In-LiLo-IgM in 
the kidneys and lungs is relatively low due to the fast 
and high liver uptake. Both in In-LiLo-IgG and lu In- 
LiLo-IgM showed low bone marrow uptake and insig­
nificant bowel excretion.
In conclusion, chelation with LiLo has a minor influ­
ence on abscess targeting of lnIn-labelled IgG compared 
with DTPA conjugation, However, differences in blood 
clearance and organ uptake do occur. On the basis of 
experiments in rats, no clear-cut preference for either
Nuclear Medicine Communications (1996) 17
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method of chelation can be expressed. rnIn-LiLo-IgM 
shows high relative accumulation in abscesses, but also 
high liver and spleen uptake. The latter renders the 11'In- 
LiLo-IgM preparation unsuitable for infection and 
inflammation imaging of the upper abdomen, but lu In- 
LiLo-IgM holds promise for imaging infection outside 
the trunk region (e.g. the peripheral musculoskeletal 
system).
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